Clinical TrialJun 25, 2026, 07:01 AM
Atea Pharma completes C-FORWARD Phase 3 enrollment for HCV drug
AI Summary
Atea Pharmaceuticals announced the completion of patient enrollment in its C-FORWARD Phase 3 clinical trial for the treatment of hepatitis C virus (HCV) outside North America. The trial enrolled over 880 treatment-naïve patients across 17 countries, evaluating the bemnifosbuvir and ruzasvir (BEM/RZR) regimen. Topline results for C-FORWARD are anticipated around year-end 2026, while results for the C-BEYOND Phase 3 trial in North America are still expected mid-2026.
Key Highlights
- Atea Pharma completed patient enrollment in C-FORWARD Phase 3 trial for HCV.
- C-FORWARD enrolled over 880 treatment-naïve patients across 17 countries.
- Topline results for C-FORWARD are expected around year-end 2026.
- Topline results for C-BEYOND (US/Canada Phase 3 trial) remain on track for mid-2026.
- Trials evaluate bemnifosbuvir and ruzasvir (BEM/RZR) against standard of care.
- BEM/RZR regimen aims for short treatment duration and low drug-drug interactions.
Price Impact
More from AVIR